Therapiestrategien bei nicht infektiösen entzündlichen Augenerkrankungen – Wann sollte welche systemische Therapie begonnen werden?

Einleitung

Zur Therapie einer Uveitis oder Skleritis werden in erster Linie topische und systemische Kortikosteroide genutzt. Abhängig von Lokalisation und Schwere der Entzündung ist hiermit häufig kurzfristig Reizfreiheit zu erzielen. Gelegentlich wird damit aber keine Rückbildung der Beschwerden erlangt, sodass eine nicht steroidale immunsuppressive Therapie erforderlich wird. In dieser Übersicht sollen die Therapiestrategien bei Patienten mit nicht infektiöser Uveitis und Skleritis unter besonderer Berücksichtigung nicht steroidaler systemischer Therapie dargelegt werden. Ziel ist es, dem Augenarzt die aktuellen entzündungshemmenden Therapieoptionen, deren Kontraindikationen und wichtige unerwünschte Medikamentenwirkungen darzulegen.

Literatur

• 1 Jabs D A, Nussenblatt R B, Rosenbaum J T. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop.  Am J Ophthalmol. 2005;  140 509-516
• 2 Gritz D C, Wong I G. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study.  Ophthalmology. 2004;  111 491-500 discussion 500
• 3 Smith J R, Mackensen F, Rosenbaum J T. Therapy insight: scleritis and its relationship to systemic autoimmune disease.  Nat Clin Pract. 2007;  3 219-226
• 4 Haynes B F, Fishman M L, Fauci A S et al. The ocular manifestations of Wegener's granulomatosis. Fifteen years experience and review of the literature.  Am J Med. 1977;  63 131-141
• 5 Dunne J A, Jacobs N, Morrison A et al. Efficacy in anterior uveitis of two known steroids and topical tolmetin.  Br J Ophthalmol. 1985;  69 120-125
• 6 Sand B B, Krogh E. Topical indometacin, a prostaglandin inhibitor, in acute anterior uveitis. A controlled clinical trial of non-steroid versus steroid anti-inflammatory treatment.  Acta Ophthalmol (Copenh). 1991;  69 145-148
• 7 Weijtens O, Feron E J, Schoemaker R C et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection.  Am J Ophthalmol. 1999;  128 192-197
• 8 Weijtens O, Schoemaker R C, Romijn F P et al. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate.  Ophthalmology. 2002;  109 1887-1891
• 9 Weijtens O, van der Sluijs F A, Schoemaker R C et al. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection.  Am J Ophthalmol. 1997;  123 358-363
• 10 Benitez-Del-Castillo J M, Garcia-Sanchez J, Iradier T et al. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis.  Eye (Lond). 2000;  14 (Pt 3A) 340-343
• 11 Hatemi G, Silman A, Bang D et al. EULAR recommendations for the management of Behcet disease.  Annals of the Rheumatic Diseases. 2008;  67 1656-1662
• 12 Sfikakis P P, Markomichelakis N, Alpsoy E et al. Anti-TNF therapy in the management of Behcet's disease – review and basis for recommendations.  Rheumatology (Oxford, England). 2007;  46 736-741
• 13 Alpsoy E, Durusoy C, Yilmaz E et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study.  Archives of Dermatology. 2002;  138 467-471
• 14 Becker M D, Heiligenhaus A, Hudde T et al. Interferon as a treatment for uveitis associated with multiple sclerosis.  Br J Ophthalmol. 2005;  89 1254-1257
• 15 Heiligenhaus A, Duck N, Michel D et al. Indication and effect of immunosuppression in patients with scleritis.  Klin Monatsbl Augenheilkd. 2003;  220 471-480
• 16 Jabs D A, Mudun A, Dunn J P et al. Episcleritis and scleritis: clinical features and treatment results.  Am J Ophthalmol. 2000;  130 469-476
• 17 Watson P G, Young R D. Scleral structure, organisation and disease. A review.  Experimental Eye Research. 2004;  78 609-623
• 18 Bauer A M, Fiehn C, Becker M D. Celecoxib, a selective inhibitor of cyclooxygenase 2 for therapy of diffuse anterior scleritis.  Am J Ophthalmol. 2005;  139 1086-1089
• 19 Sainz de la Maza M, Jabbur N S, Foster C S. An analysis of therapeutic decision for scleritis.  Ophthalmology. 1993;  100 1372-1376
• 20 Sen H N, Suhler E B, Al-Khatib S Q et al. Mycophenolate mofetil for the treatment of scleritis.  Ophthalmology. 2003;  110 1750-1755
• 21 Soukiasian S H, Foster C S, Raizman M B. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease.  Am J Ophthalmol. 1994;  118 601-611
• 22 Wakefield D, McCluskey P. Cyclosporin therapy for severe scleritis.  Br J Ophthalmol. 1989;  73 743-746
• 23 Taylor S R, Salama A D, Joshi L et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis.  Arthritis and Rheumatism. 2009;  60 1540-1547
• 24 Doctor P, Sultan A, Syed S et al. Infliximab for the treatment of refractory scleritis.  Br J Ophthalmology. 2010;  94 (5) 579-583
• 25 Meyer P A, Watson P G, Franks W et al. ‘Pulsed immunosuppressive therapy in the treatment of immunologically induced corneal and scleral disease.  Eye. 1987;  1 (Pt 4) 487-495
• 26 Wessels J A, Huizinga T W, Guchelaar H J. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis.  Rheumatology. 2008;  47 249-255
• 27 Samson C M, Waheed N, Baltatzis S et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients.  Ophthalmology. 2001;  108 1134-1139
• 28 van Ede A E, Laan R F, Rood M J et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.  Arthritis Rheum. 2001;  44 1515-1524
• 29 Gangaputra S, Newcomb C W, Liesegang T L et al. Methotrexate for ocular inflammatory diseases.  Ophthalmology. 2009;  116 2188-2198 e2181
• 30 Hesselink D A, Baarsma G S, Kuijpers R W et al. Experience with cyclosporine in endogenous uveitis posterior.  Transplant Proc. 2004;  36 372S-377S
• 31 Zierhut M, Stubiger N, Aboalchamat W et al. Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis.  Ophthalmologe. 2001;  98 647-651
• 32 Baltatzis S, Tufail F, Yu E N et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders.  Ophthalmology. 2003;  110 1061-1065
• 33 Daniel E, Thorne J E, Newcomb C W et al. Mycophenolate mofetil for ocular inflammation.  Am J Ophthalmol. 2009;  149 423-432 e421-422
• 34 Pasadhika S, Kempen J H, Newcomb C W et al. Azathioprine for ocular inflammatory diseases.  Am J Ophthalmol. 2009;  148 500-509 e502
• 35 Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period.  J Rheumatol. 2003;  30 1277-1279
• 36 Pujari S S, Kempen J H, Newcomb C W et al. Cyclophosphamide for ocular inflammatory diseases.  Ophthalmology. 2009;  117 356-365
• 37 Dick A D, Forrester J V, Liversidge J et al. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU).  Progress in Retinal and Eye Research. 2004;  23 617-637
• 38 Diel R, Hauer B, Loddenkemper R et al. Empfehlungen für das Tuberkulose-Screening vor Gabe von TNF-α-Inhibitoren bei rheumatischen Erkrankungen.  Pneumologie. 2009;  63 329-334
• 39 Foster C S, Tufail F, Waheed N K et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate.  Archives of Ophthalmology. 2003;  121 437-440
• 40 Galor A, Perez V L, Hammel J P et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.  Ophthalmology. 2006;  113 2317-2323
• 41 Sieper J, Koenig A, Baumgartner S et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials.  Annals of the Rheumatic Diseases. 2010;  69 226-229
• 42 Diaz-Llopis M, Garcia-Delpech S, Salom D et al. Adalimumab therapy for refractory uveitis: a pilot study.  J Ocul Pharmacol Ther. 2008;  24 351-361
• 43 Suhler E B, Smith J R, Giles T R et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial.  Archives of Ophthalmology. 2009;  127 819-822
• 44 Suhler E B, Smith J R, Wertheim M S et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.  Archives of Ophthalmology. 2005;  123 903-912
• 45 Tugal-Tutkun I, Mudun A, Urgancioglu M et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial.  Arthritis and Rheumatism. 2005;  52 2478-2484
• 46 Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis.  Graefes Arch Clin Exp Ophthalmol. 2006;  244 1692-1695
• 47 Gueudry J, Wechsler B, Terrada C et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease.  Am J Ophthalmol. 2008;  146 837-844 e831
• 48 Deuter C M, Kotter I, Gunaydin I et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis.  Br J Ophthalmol. 2009;  93 906-913
• 49 Sadreddini S, Noshad H, Molaeefard M et al. Treatment of retinal vasculitis in Behcet's disease with rituximab.  Modern Rheumatology/The Japan Rheumatism Association. 2008;  18 306-308
• 50 Tappeiner C, Heinz C, Specker C et al. Rituximab as a treatment option for refractory endogenous anterior uveitis.  Ophthalmic Research. 2007;  39 184-186